Pharmacists must be experts on follow-on biologics (FOBs), including biosimilars, so they can provide education to health professionals about safe prescribing and use, which ultimately affects patient care.
Roy Daniel Pollom, MD
Advertisement
Articles by Roy Daniel Pollom, MD
Health care practitioners need to prepare for myriad questions regarding biosimilars and follow-on biologic drugs as they enter the market.
Advertisement
Latest Updated Articles
Biosimilars and Follow-on BiologicsPublished: September 28th 2017 | Updated:
Biosimilars and Follow-on Biologics: A Pharmacist OpportunityPublished: October 12th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
2
OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why
3
FDA Updates Boxed Warning for Cilta-Cel Following Reports of Immune Effector Cell–Associated Enterocolitis
4
Medetomidine: The Demon in the Illicit Fentanyl Supply
5
